1. Real Structural Valve Deterioration of the Mitroflow Aortic Prosthesis: Competing Risk Analysis;Díaz;Rev Esp Cardiol.,2017
2. Early structural valve deterioration of Mitroflow aortic bioprosthesis: mode, incidence, and impact on outcome in a large cohort of patients;Sénage;Circulation.,2014
3. Agence Nationale de Sécurité du Médicament et des Produits de Santé. Recommandations sur l’utilisation des valves cardiaques chirurgicales biologiques Mitroflow 19mm de la société LivaNova [citado 18 Jun 2017]. Disponible en: http://ansm.sante.fr/var/ansm_site/storage/original/application/36545206c6c90e45e306b3b2283a30d9.pdf.
4. Medicines and Healthcare products Regulatory Agency. Biological replacement pericardial aortic heart valve: Mitroflow LX (sizes 19mm and 21mm)—risk of early structural valve deterioration [citado 18 Jun 2017]. Disponible en: https://www.gov.uk/drug-device-alerts/biological-replacement-pericardial-aortic-heart-valve-mitroflow-lx-sizes-19mm-and-21mm-risk-of-early-structural-valve-deterioration.
5. Effect of bioprostheses anti-calcification treatment: comparative follow-up between Mitroflow LX and Magna pericardial xenografts using a propensity score-weighted analysis;Blasco-Lucas;Interact Cardiovasc Thorac Surg.,2017